

CN 0 (Cytokines); 0 (Extracellular Matrix Proteins); 0 (Fibronectins); 0 (Interleukin-6); 0 (Tumor Necrosis Factor)

L151 ANSWER 4 OF 4 MEDLINE

AN 93065133 MEDLINE

DN 93065133 PubMed ID: 1437506

TI Immunomodulators. Future prospects.

AU Takx-Kohlen B C

CS Department of Clinical Pharmacy and Toxicology, University Hospital of Maastricht, The Netherlands.

SO PHARMACEUTISCH WEEKBLAD. SCIENTIFIC EDITION, (1992 Aug 21) 14 (4A) 245-52.
Ref: 46

Journal code: 7907992. ISSN: 0167-6555.

CY Netherlands

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, TUTORIAL)

LA English

FS Priority Journals

EM 199212

ED Entered STN: 19930122

Last Updated on STN: 19930122

Entered Medline: 19921204

AB The future role of the immunomodulators in medical practice is yet to be defined. The key question is whether these new substances will bring remarkable progress in transplantation or in the treatment of such conditions as cancer, AIDS, and **autoimmune** diseases, or whether they will be of only minor adjunctive importance. As background to the discussion of immunomodulating agents, the immune system is explained, with emphasis on the roles of T and B lymphocytes, **macrophages**, phagocytes, human leukocyte antigen and the complement system. Special attention is given to the cytokines, particularly the lymphokines. The immunomodulators can be divided into three main groups: immunosuppressive agents, such as FK 506 and rapamycin; immunostimulating agents, of which BCG vaccine is most important; and the remaining immunomodulators, which include the biological response modifiers. The last group, which encompasses the **colony-stimulating factors** (GM-CSF, G-CSF, and M-CSF), the interleukins, the interferons, and the tumour necrosis factors, is described in detail. Innovative research and medical applications of these cytokines, including indications, contraindications, and adverse reactions, are discussed. The role of **monoclonal antibodies** against endotoxins is also described.

CT Check Tags: Animal; Human

*Adjuvants, Immunologic: TU, therapeutic use

Forecasting

CN 0 (Adjuvants, Immunologic)

=> d his

(FILE 'HOME' ENTERED AT 10:59:27 ON 09 DEC 2002)

SET COST OFF

FILE 'REGISTRY' ENTERED AT 10:59:39 ON 09 DEC 2002

E COLONY STIMULATING FACTOR/CN

L1 1 S E9

E MCSF/CN

E M-CSF/CN

L2 2 S E3

L3 1 S L2 NOT SQL/FA

FILE 'HCAPLUS' ENTERED AT 11:01:08 ON 09 DEC 2002

L4	2122	S	L1
L5	3184	S	L3
L6	17804	S	COLONY STIMULATING FACTOR
L7	10562	S	MACROPHAGE COLONY STIMULATING FACTOR
L8	28846	S	CSF OR MCSF OR M CSF
L9	7	S	M COLONY STIMULATING FACTOR
L10	389	S	MONOCYTE COLONY STIMULATING FACTOR
L11	6	S	MACROPHAGE MONOCYTE COLONY STIMULATING FACTOR
L12	9	S	COLONY FORMATION STIMULATING FACTOR
L13	2	S	NEUTROPHIL ALKALINE PHOSPHATASE INDUCING FACTOR
L14	34366	S	L4-L13 E INFLAMMATION/CT
L15	3952	S	E9, E24 E E3+ALL
L16	70854	S	E2+NT E E36+ALL
L17	27318	S	E3+NT E E18+ALL
L18	6730	S	E6, E5+NT E E10+ALL
L19	10558	S	E2 E PSORIASIS/CT
L20	25	S	E4, E5 E E3+ALL
L21	6351	S	E4 E E14 E E7+ALL
L22	193	S	E2 E ANTIPSOR/CT E ANTI-PSOR/CT E RHEUMATOID ARTHRITIS/CT
L23	229	S	E4, E5 E E3+ALL
L24	10055	S	E10, E11, E9+NT
L25	1359	S	E20+NT E E20+ALL
L26	1662	S	E4, E5 E ANTIARTHRIT/CT E E4+ALL
L27	4389	S	E5, E4+NT E ARTHRITIS/CT
L28	7433	S	E4-E24 E E3+ALL
L29	19347	S	E6+NT E SEPSIS/CT
L30	818	S	E4-E6, E8-E11 E E3+ALL
L31	8169	S	E4, E3+NT E ATHEROSCLERO/CT
L32	78	S	E5 E E4+ALL
L33	22794	S	E7-E9, E6+NT E ATHEROSCLERO/CT E E6+ALL
L34	4147	S	E2 E ANTIATHEROSCLERO/CT E E6+ALL E AUTOIMMUN/CT
L35	1	S	E10 E E9+ALL E E2+ALL
L36	22243	S	E3, E2+NT E OSTEROPOROSIS/CT

L37	2793	S E4-E6, E8, E9 E E7+ALL
L38	2079	S E2 E OSTEOPOROSIS/CT E E3+ALL
L39	7747	S E6+NT E BONE DENSITY/CT E E2+ALL
L40	906	S E2 E BONE/CT
L41	5694	S E15, E56, E57 E E134+ALL
L42	813	S E2 E BONE REMINERAL/CT E E4+ALL
L43	680	S E2 E BONE, DISEASE/CT
L44	105	S E15
L45	8359	S E43, E44
L46	249	S E69, E70 E RESORPTION/CT E E4+ALL
L47	275477	S ?INFLAM? OR ?OSTEOPOR? OR ?OESTEOPOR? OR ?AUTOIMMUN? OR IMMUN
L48	5342	S L14 AND L15-L47
L49	828	S L48 AND L4, L5
L50	6	S L49 AND MAB
L51	65	S L49 AND MONOCLON?(L)ANTIBOD?
L52	86	S L49 AND ANTIBOD?/CW
L53	86	S L49 AND ANTIBOD?/CT
L54	113	S L50-L53
L55	27	S L54 AND CHEMOKIN? E CHEMOKINE/CT E E35+ALL
L56	6395	S E6, E5+NT E E18+ALL
L57	4479	S E12, E13, E11+NT
L58	26	S L54 AND L56, L57
L59	29	S L55, L58
L60	1	S L59 AND PROMOTER/TI
L61	4	S L59 AND ANTIBOD?/TI SEL DN AN 4
L62	1	S L61 AND E1-E3
L63	2	S L60, L62 E SHOCK/CT E E4+ALL
L64	10981	S E5, E6, E4+NT E E23+ALL
L65	3950	S E3, E2+NT E E19+ALL
L66	11191	S E12-E14, E11+NT E E23+ALL
L67	942	S E5, E4+NT E E16+ALL E E24+ALL
L68	296	S L14 AND L64-L57
L69	42	S L68 AND (MAB OR MONOCLON?(L)ANTIBOD?)
L70	58	S L68 AND ANTIBOD?/CT, CW
L71	43	S L70 AND CHEMOKIN? E CHEMOKINE/CT E E35+ALL
L72	6395	S E6, E5+NT E E18+ALL

L73 4479 S E12,E13,E11+NT
L74 43 S L70 AND L72,L73
L75 17 S L71,L74 NOT L59
E DEVALARAJA M/AU
L76 10 S E4,E5
E LOW J/AU
L77 12 S E3,E9,E10
L78 16 S E55-E57
L79 36 S L76-L78
L80 1 S L79 AND L14
L81 2 S L59 AND INHIBIT?/TI
L82 1 S L81 NOT METALLOPROT?
L83 2 S L60,L82 AND L4-L82
E PFIZER/PA,CS
L84 9784 S E3,E4
L85 28 S L84 AND L14
L86 13 S L85 AND L48
SEL DN AN 7 9
L87 2 S L86 AND E1-E6
L88 4 S L83,L87
L89 4 S L88 AND L4-L88
L90 1 S L89 AND RESPIR?
L91 4 S L89,L90
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 11:48:54 ON 09 DEC 2002
L92 2 S E7-E8

FILE 'REGISTRY' ENTERED AT 11:49:07 ON 09 DEC 2002

FILE 'HCAPLUS' ENTERED AT 11:49:20 ON 09 DEC 2002

FILE 'WPIX' ENTERED AT 11:51:26 ON 09 DEC 2002
E A61K039-39/IC, ICM, ICS
L93 8209 S E12-E14
E C07K016-24/IC, ICM, ICS
L94 628 S E3-E5
L95 277 S L93 AND L94
L96 2601 S L6-L13
L97 146 S L93 AND L96
L98 12 S L95 AND L97
L99 256 S L9 OR L10 OR L11 OR MCSF OR M CSF
L100 24 S L99 AND L93
L101 24 S L99/ABEX
L102 2 S L101 AND L93
L103 25 S L100,L102
E US2000-190842/AP, PRN
E US2001-885259/AP, PRN
E DEVALARAJA M/AU
E LOW J/AU
L104 9 S E3,E7
L105 0 S L104 AND L93-L103
L106 3 S L104 AND CHEMOKIN?
L107 5 S L104 AND ?INFLAM?
L108 5 S L106,L107

FILE 'WPIX' ENTERED AT 12:03:21 ON 09 DEC 2002
L109 0 S PFIZ?/PA AND L99
L110 0 S PFIZ?/PA AND L94

FILE 'MEDLINE' ENTERED AT 12:04:13 ON 09 DEC 2002
L111 2291 S L99
L112 2289 S L3

L113	0	S	L1
L114	25385	S	L6
L115	3139	S	L111, L112 AND L114
L116	3393	S	L111, L112, L115
		E	COLONY-/CT
		E	E36+ALL
L117	6774	S	E66, E34
L118	7647	S	L116, L117
L119	804	S	L118 AND L47
		E	INFLAMMATION/CT
		E	E3+ALL
L120	94	S	L118 AND E4+NT
L121	7	S	L118 AND E38+NT
L122	209	S	L118 AND E39+NT
		E	OSTEOPOROSIS/CT
		E	E3+ALL
L123	11	S	L118 AND E4+NT
		E	BONE DENSITY/CT
		E	E3+ALL
L124	7	S	L118 AND E4+NT
		E	BONE DEMINERAL/CT
		E	E12+ALL
L125	0	S	L118 AND E5+NT
		E	BONE REMINERAL/CT
		E	E13+ALL
L126	128	S	L118 AND E12+NT
		E	CLIM/CT
		E	E4+ALL
L127	1	S	L118 AND E4+NT AND ("BONE AND BONES"+NT OR BONE DISEASES, MET
		E	AUTOIMMUNE/CT
L128	107	S	L118 AND E16+NT
		E	ATHEROSCLER/CT
		E	E8+ALL
L129	49	S	L118 AND E2+NT
		E	E2+ALL
		E	SEPSIS/CT
		E	E3+ALL
L130	34	S	L118 AND E4+NT
		E	ASTHMA/CT
		E	E3+ALL
L131	7	S	L118 AND E15+NT
L132	61	S	L118 AND E27+NT
		E	ARTHRITIS/CT
		E	E3+ALL
L133	62	S	L118 AND E4+NT
L134	1	S	L118 AND (E41+NT OR E42+NT)
		E	PSORIASIS/CT
		E	E3+ALL
L135	6	S	L118 AND E5+NT
L136	1163	S	L119-L135
		E	MONOCLONAL ANTIBODY/CT
		E	E1+ALL
L137	0	S	L135 AND E2+NT
		E	E2+ALL
L138	0	S	L135 AND E7+NT
L139	10	S	L136 AND MAB
L140	69	S	L136 AND MONOCLON? (L) ANTIBOD?
L141	74	S	L139, L140
		E	DEVALARAJA M/AU
L142	8	S	E4
		E	LOW J/AU
L143	75	S	E3, E8
L144	0	S	L142, L143 AND L118

L145 55 S L141 AND L116
L146 55 S L118 AND L145
SEL DN AN 9 11 17 50
L147 4 S L146 AND E1-E12
L148 4 S L147 AND L111-L147
L149 4 S L147 AND (CSF# OR CSF 1)
L150 4 S L147 AND MACROPHAG?
L151 4 S L147-L150

FILE 'MEDLINE' ENTERED AT 12:28:45 ON 09 DEC 2002

FILE 'BIOSIS' ENTERED AT 12:28:51 ON 09 DEC 2002

E DEVALARAJA M/AU
L152 13 S E2,E4,E5
E LOW J/AU
L153 49 S E3,E12,E13
E LOW JOE/AU
L154 6 S E3,E9,E10
L155 68 S L152-L154
L156 0 S L14 AND L155
L157 0 S L152 AND L153,L154